Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more
Dishman Carbogen Amcis Limited (DCAL) - Net Assets
Latest net assets as of September 2025: ₹63.65 Billion INR
Based on the latest financial reports, Dishman Carbogen Amcis Limited (DCAL) has net assets worth ₹63.65 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹111.09 Billion) and total liabilities (₹47.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹63.65 Billion |
| % of Total Assets | 57.29% |
| Annual Growth Rate | 20.2% |
| 5-Year Change | 2.33% |
| 10-Year Change | 301.62% |
| Growth Volatility | 51.61 |
Dishman Carbogen Amcis Limited - Net Assets Trend (2005–2025)
This chart illustrates how Dishman Carbogen Amcis Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dishman Carbogen Amcis Limited (2005–2025)
The table below shows the annual net assets of Dishman Carbogen Amcis Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹58.32 Billion | +3.63% |
| 2024-03-31 | ₹56.27 Billion | -3.14% |
| 2023-03-31 | ₹58.10 Billion | +4.70% |
| 2022-03-31 | ₹55.49 Billion | -2.63% |
| 2021-03-31 | ₹56.99 Billion | -0.28% |
| 2020-03-31 | ₹57.15 Billion | +6.25% |
| 2019-03-31 | ₹53.79 Billion | +5.32% |
| 2018-03-31 | ₹51.07 Billion | +6.09% |
| 2017-03-31 | ₹48.14 Billion | +231.54% |
| 2016-03-31 | ₹14.52 Billion | +16.92% |
| 2015-03-31 | ₹12.42 Billion | +3.30% |
| 2014-03-31 | ₹12.02 Billion | +13.99% |
| 2013-03-31 | ₹10.55 Billion | +13.54% |
| 2012-03-31 | ₹9.29 Billion | +5.65% |
| 2011-03-31 | ₹8.79 Billion | +12.10% |
| 2010-03-31 | ₹7.84 Billion | +11.34% |
| 2009-03-31 | ₹7.04 Billion | +22.83% |
| 2008-03-31 | ₹5.73 Billion | +80.36% |
| 2007-03-31 | ₹3.18 Billion | +68.66% |
| 2006-03-31 | ₹1.89 Billion | +28.18% |
| 2005-03-31 | ₹1.47 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dishman Carbogen Amcis Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 212900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.13 Billion | 3.65% |
| Common Stock | ₹313.60 Million | 0.54% |
| Other Comprehensive Income | ₹8.48 Billion | 14.55% |
| Other Components | ₹47.39 Billion | 81.26% |
| Total Equity | ₹58.32 Billion | 100.00% |
Dishman Carbogen Amcis Limited Competitors by Market Cap
The table below lists competitors of Dishman Carbogen Amcis Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yirendai Ltd
NYSE:YRD
|
$103.78 Million |
|
Good Finance Securities Co Ltd
TWO:6021
|
$103.80 Million |
|
Hangzhou Yitong New Material Co. LTD
SHE:300930
|
$103.83 Million |
|
Servicios Corporativos Javer
MX:JAVER
|
$103.84 Million |
|
Blaize Holdings, Inc. Common Stock
PINK:BZAI
|
$103.73 Million |
|
KOFOLA CESKOSLOVE. KC 50
F:48K
|
$103.71 Million |
|
FG Merger II Corp. Common stock
NASDAQ:FGMC
|
$103.68 Million |
|
Aimia Inc
PINK:AIMFF
|
$103.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dishman Carbogen Amcis Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 56,275,000,000 to 58,315,200,000, a change of 2,040,200,000 (3.6%).
- Net income of 32,400,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 1,652,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹32.40 Million | +0.06% |
| Other Comprehensive Income | ₹1.65 Billion | +2.83% |
| Other Changes | ₹355.80 Million | +0.61% |
| Total Change | ₹- | 3.63% |
Book Value vs Market Value Analysis
This analysis compares Dishman Carbogen Amcis Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 15.09x to 0.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹10.84 | ₹163.53 | x |
| 2006-03-31 | ₹11.59 | ₹163.53 | x |
| 2007-03-31 | ₹19.57 | ₹163.53 | x |
| 2008-03-31 | ₹35.25 | ₹163.53 | x |
| 2009-03-31 | ₹43.30 | ₹163.53 | x |
| 2010-03-31 | ₹48.21 | ₹163.53 | x |
| 2011-03-31 | ₹54.47 | ₹163.53 | x |
| 2012-03-31 | ₹57.55 | ₹163.53 | x |
| 2013-03-31 | ₹63.87 | ₹163.53 | x |
| 2014-03-31 | ₹72.94 | ₹163.53 | x |
| 2015-03-31 | ₹76.69 | ₹163.53 | x |
| 2016-03-31 | ₹89.94 | ₹163.53 | x |
| 2017-03-31 | ₹298.27 | ₹163.53 | x |
| 2018-03-31 | ₹316.45 | ₹163.53 | x |
| 2019-03-31 | ₹333.29 | ₹163.53 | x |
| 2020-03-31 | ₹355.03 | ₹163.53 | x |
| 2021-03-31 | ₹363.46 | ₹163.53 | x |
| 2022-03-31 | ₹353.92 | ₹163.53 | x |
| 2023-03-31 | ₹370.55 | ₹163.53 | x |
| 2024-03-31 | ₹358.94 | ₹163.53 | x |
| 2025-03-31 | ₹377.97 | ₹163.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dishman Carbogen Amcis Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.12%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.71x
- Recent ROE (0.06%) is below the historical average (9.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 22.15% | 17.47% | 0.58x | 2.19x | ₹178.65 Million |
| 2006 | 26.97% | 18.33% | 0.47x | 3.16x | ₹319.92 Million |
| 2007 | 28.81% | 15.85% | 0.50x | 3.65x | ₹598.76 Million |
| 2008 | 20.87% | 14.91% | 0.55x | 2.56x | ₹623.59 Million |
| 2009 | 20.75% | 13.76% | 0.63x | 2.40x | ₹757.52 Million |
| 2010 | 14.99% | 12.84% | 0.51x | 2.29x | ₹391.50 Million |
| 2011 | 9.10% | 7.76% | 0.50x | 2.37x | ₹-79.04 Million |
| 2012 | 6.11% | 5.05% | 0.50x | 2.42x | ₹-361.25 Million |
| 2013 | 9.73% | 7.88% | 0.55x | 2.25x | ₹-27.86 Million |
| 2014 | 9.28% | 7.89% | 0.54x | 2.19x | ₹-84.48 Million |
| 2015 | 9.68% | 7.54% | 0.56x | 2.27x | ₹-39.70 Million |
| 2016 | 11.79% | 10.72% | 0.54x | 2.05x | ₹259.55 Million |
| 2017 | 3.02% | 8.49% | 0.26x | 1.37x | ₹-3.36 Billion |
| 2018 | 3.03% | 9.35% | 0.23x | 1.41x | ₹-3.56 Billion |
| 2019 | 3.91% | 10.96% | 0.26x | 1.36x | ₹-3.28 Billion |
| 2020 | 2.77% | 7.76% | 0.25x | 1.43x | ₹-4.13 Billion |
| 2021 | -2.90% | -8.64% | 0.23x | 1.47x | ₹-7.35 Billion |
| 2022 | 0.32% | 0.84% | 0.25x | 1.56x | ₹-5.37 Billion |
| 2023 | -0.51% | -1.29% | 0.24x | 1.63x | ₹-6.11 Billion |
| 2024 | -2.73% | -5.87% | 0.27x | 1.70x | ₹-7.16 Billion |
| 2025 | 0.06% | 0.12% | 0.27x | 1.71x | ₹-5.80 Billion |
Industry Comparison
This section compares Dishman Carbogen Amcis Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,296,188,767
- Average return on equity (ROE) among peers: -7.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dishman Carbogen Amcis Limited (DCAL) | ₹63.65 Billion | 22.15% | 0.75x | $103.76 Million |
| Anthem Biosciences Ltd (ANTHEM) | $17.41 Billion | 22.13% | 0.16x | $17.29 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $10.46 Million |
| Biocon Limited (BIOCON) | $14.77 Billion | 31.41% | 0.41x | $2.54 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $134.93 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $346.78 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $129.20K |
| Lyka Labs Limited (LYKALABS) | $582.36 Million | -29.66% | 3.04x | $8.51 Million |
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | $75.29 Billion | 0.00% | 0.00x | $1.21 Billion |
| Panacea Biotec Limited (PANACEABIO) | $1.96 Billion | -99.24% | 6.10x | $56.46 Million |